Education
About Us
Working with TipRanks
Follow Us
Oryzon Genomics SA (DE:ORN)
FRANKFURT:ORN
ORN Stock Chart & Stats
€3.04
<€0.01(0.55%)
At close: 4:00 PM EST
€3.04
<€0.01(0.55%)
Day’s Range― - ―
52-Week Range€2.36 - €3.98
Previous CloseN/A
Volume0.00
Average Volume (3M)249.00
Market Cap
€220.79M
Enterprise Value€195.50M
Total Cash (Recent Filing)€31.11M
Total Debt (Recent Filing)€13.73M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
May 18, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding79,887,700
10 Day Avg. Volume325
30 Day Avg. Volume249
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€3.00M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA relatively strong balance sheet with sizable equity and low leverage gives Oryzon financial flexibility to fund clinical programs and R&D over the medium term. This reduces near-term refinancing urgency and supports continued development without immediate asset sales or drastic cost cutting.
Clinical Progress – EMA Phase II ApprovalEMA authorization to start a Phase II IDEAL study is a structural clinical milestone that advances iadademstat into efficacy-focused testing. Successful execution can produce durable clinical data, improve regulatory visibility, and materially increase partnering or financing options over 2–6 months and beyond.
Management Strengthening (CMO Hire)Hiring an experienced, Harvard-trained CMO with deep neuroscience development experience strengthens clinical leadership and trial design capabilities. Improved medical leadership enhances chances of efficient CNS program execution, regulatory engagement, and credible partnership discussions long term.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow signals ongoing cash burn to fund operations and trials. That structural cash consumption necessitates recurrent external financing or partnerships, raising dilution risk and creating dependency on successful near-term milestones to sustain the business.
Irregular And Weak RevenueHighly irregular revenue, including multiple years with zero sales, undermines predictability and the company's ability to self-fund. Reliance on non-recurring or sporadic income complicates budgeting, increases financing frequency, and weakens the firm's capacity to scale operations independently.
Ongoing Losses And Negative ROEOryzon's recurring operating and net losses produce negative returns on equity, indicating invested capital is not yet productive. Over the medium term this pressures margins and forces prioritization of programs or external funding, making long-term sustainability contingent on successful clinical outcomes or partnerships.
Oryzon Genomics SA News
ORN FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was €2.36 and its highest was €3.98 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is €220.79M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is May 18, 2026 which is in 73 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on Feb 27, 2026. The company reported -€0.02 earnings per share for the quarter, beating the consensus estimate of -€0.034 by €0.014.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Overvalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -0.04.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 79,887,700 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of -€0.02 in its last earnings report, beating expectations of -€0.034. Following the earnings report the stock price went up 1.286%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in DE:ORN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Technical Analysis
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
ADL Bionatur Solutions SA
―
Atrys Health SA
―
Options Prices
Currently, No data available
---